MSL/北京/Major/Responsibilities/Field/based/KOL/Speaker/Development/Identification/mapping/of/KOLs/Develop/professional/relationships/with/the/targeting/KOLs/and/build/advocacy/and/gain/contributions/of/KOL/decision/makers/Proactively/Visit/Track/analyze/and/reports/targeting/KOLs/advocacy/contribution/and/publication/status/in/required/system/and/KOL/management/tool/as/appropriate/Provide/and/discuss/scientific/information/and/data/regarding/new/launched/products/to/healthcare/professionals/to/ensure/quality/and/accuracy/of/key/medical/and/scientific/information/on/new/treatment/options/by/face/to/face/visits/speaker/training/and/scientific/communications/Scientific/support/of/speaker/training/activities/in/the/region/with/timely/feedback/Information/Management/and/Meeting/Events/May/function/as/the/Novartis/medical/speaker/to/present/at/Novartis/Society/sponsored/activities/for/up/to/date/data/based/scientific/and/clinical/information/on/Novartis/product/s/Liaise/and/provide/up/to/date/medical/support/to/facilitate/listing/of/products/in/medical/guidelines/RDL/formularies/as/appropriate/Participate/in/cross/functional/meetings/as/appropriate/and/sharing/feedback/of/targeting/KOLs/advocacy/and/contribution/Prepare/and/tailor/speaker/slides/in/alignment/with/NP4/and/Medical/strategies/Manage/unsolicited/requests/objections/comply/with/NP4/and/China/legal/and/regulatory/requirements/Clinical/Trials/and/Medical/Affairs/Studies/Contribute/to/the/identification/and/recommendation/of/appropriate/KOL/involvement/and/participation/in/Novartis/sponsored/clinical/trials/PMS/Phase/III/and/Phase/IV/studies/from/assigned/region/Conduct/or/Coordinate/third/party/trials/animal/studies/registry/or/epidemiology/programs/in/assigned/region/and/operation/follow/up/the/above/program/with/Trial/Master/File/to/archive/all/relevant/documents/in/align/with/Novartis/SOPs/Evaluate/requests/to/research/fund/as/they/pertain/to/Medical/Affairs/activities/Required/Knowledge/and/Skill/Languages/Fluent/in/Chinese/and/English/oral/and/written/Experience/Professional/requirement/Proven/ability/to/develop/and/foster/peer/to/peer/credible/relationships/in/order/to/educate/and/influence/KOL/s/decision/makers/Working/knowledge/of/the/Healthcare/System/and/of/the/clinical/trial/and/research/procedures/as/well/as/the/guidelines/GCP/and/other/ethical/guidelines/relevant/to/the/pharmaceutical/industry/Thorough/knowledge/of/clinical/medicine/disease/management/and/medical/research/in/at/least/one/therapeutic/area/Ability/to/synthesize/recent/scientific/information/analyze/within/strategic/and/regulatory/settings/Proven/ability/to/use/IT/tools/and/interface/effectively/with/a/variety/of/technical/platforms/Strong/personal/integrity/and/customer/focus/Excellent/interpersonal/communication/negotiation/and/advanced/presentation/skills/Effectively/contribute/to/multifunctional/teams/Must/be/able/to/adapt/organize/prioritize/and/work/effectively/in/a/constantly/changing/field/based/environment/10/Clinical/Master/degree/or/highe/职能/类别/医药/学术/推广/医药/技术/研发/管理/人员/管理人员/分享/微信/邮件/制药/生物/工程/生物工程/北京/诺华/制药/有限/公司/有限公司/开发/生产/销售/治疗/多种/疾病/创新/处方/方药/处方药/涵盖/疾病/领域/包括/心血/血管/心血管/内分/分泌/内分泌/肿瘤/感染/抗感染/风湿/疼痛/骨质/疏松/移植/免疫/中枢/神经/中枢神经/眼科/北京/诺华/制药/曾/获得/雇主/最负/社会/责任/企业/殊荣/诺华/中文/取意/承诺/中华/承诺/不断/创新/不断创新/产品/服务/致力/致力于/提高/中国/健康/水平/生活/质量/北京/诺华/制药/成立/1987/年/总部/设在/北京/隶属/属于/隶属于/瑞士/诺华/公司/诺华/公司/致力/致力于/患者/社会/提供/创新/医药/保健/医药保健/解决/方案/解决方案/满足/变化/健康/需求/2011/年/集团/持续/经营/业务/实现/净/销售/586/美元/亿美元/集团/研发/投入/约/96/美元/亿美元/去除/减值/摊销/后/92/美元/亿美元/诺华/集团/总部/位于/瑞士/巴塞/塞尔/巴塞尔/业务/遍及/全球/140/多个/国家/地区/拥有/124/000/位/全职/员工/诺华/集团/立足/中国/长期/发展/重要/战略/投资/包括/位于/上海/综合/合性/综合性/生物/医学/生物医学/研发/中心/位于/北京/昌平/制剂/生产/工厂/江苏/常熟/原料/原料药/生产/工厂/如需/信息/敬请/登录/公司/网站/http/www/novartis/com/http/www/novartis/com/cn/
